Scouting report · CMPS
Teri Loxam
COMPASS Pathways CFO since March 2024; ex-Merck IR head and three-time biotech CFO
- Born / age
- (54)
- Role
- Chief Financial Officer
- In the role
- 3 yr
- Education
- MBA University of California, Irvine, Paul Merage School of Business
- Front Office rank
- not ranked yet
CMPS
Stake value—no holding or price on file
—thin record
Scouting sheetas of 25 Sep 2026
Delivers guidance—no promises on the record yet
Answers the question—no call reviewed yet
Capital allocation—company not reviewed yet
Pay design40strategic, individual, time only · 99.2% for · company lost money
Skin in the game—no holding or price on file
—Hit rate
—Pay at risk
99%Say-on-pay
—Airtime on calls
- Beat
- 0
- Met
- 0
- Missed
- 0
- Withdrawn
- 0
- Still open
- 0
- Answers on calls
- 0
- Questions dodged
- 0
- Dodges / 100 answers
- —
Personal and ownership data
What to weigh
Watch 5
- Three CFO jobs in the four years before COMPASS: SQZ (27 months), Kira (17 months) and Gameto (about 6 months)src
- Chairs two outside public-company audit committees (Vaxcyte, Cardiol) while CFO of a company preparing its first NDA and launchsrc
- Equity pay is time-vested options and RSUs with no performance condition. The 2025 bonus mixed corporate goals (scored 100%) with individual performancesrc
- April 2025 amendment: all time-based equity vests in full on termination without cause or good-reason resignation within 12 months of a change in controlsrc
- Owns 26,893 ADSs outright; with 94,909 exercisable options her holding is about 0.09%. No open-market trades in the last 12 monthssrc
Pay
Salary and otherBonus, stock, options, incentive
The table
- Bonus pays on
- Cash bonus at a target of 45% of salary (cap 125% of target) on corporate goals plus individual performance. 2025 paid at 100% of target ($220,500)
- Long-term award pays on
- Annual market-priced options (76,000 in 2025) and RSUs (25,000). Time-vested, no performance conditionsrc
- Pay at risk not on file
- Pays on returns strategic, individual, time only
- Shareholder vote 99.2% for
- Pay vs profit company lost money
Career
- 2024-03 – now
- 2023-12 – 2024-03
- 2023-04 – 2023-10
- 2021-11 – 2023-04Kira Pharmaceuticals (private, clinical-stage biotech)src
Chief Financial Officer & Chief Operating Officer - 2019-08 – 2021-11SQZ Biotechnologiessrc
Chief Financial Officer
Company bio credits her with leading SQZ's IPO and raising over $200m in her first 18 months (WS-bio) - 2015-08 – 2019-08
- 2012-07 – 2015-08
- 2001-06 – 2012-07Bristol-Myers Squibbsrc
Roles of increasing responsibility across Strategy, Treasury and Investor Relations
Not located: 2023-10 to 2023-12, between Gameto and the COMPASS consulting role, not described; career before June 2001 not located beyond the company bio's statement that she began as a marine biologist
The promise ledger
No promise on the record yet: the research routine has not scored this company's guidance.
Background
- Family The 2026 proxy states there are no family relationships among any directors or executive officerssrc
- Boards Director and audit committee chair, Vaxcyte, Inc. (Nasdaq: PCVX), since September 2021src
- Boards Director and audit committee chair, Cardiol Therapeutics Inc. (Nasdaq/TSX: CRDL), since May 2022src
- Giving Board member of Warriorside, a veteran-founded nonprofit working on suicide, depression and disconnection among veterans and first responderssrc
- Personal Says she began her career as a marine biologist before moving into businesssrc
Sources8
- Filing COMPASS Pathways plc DEF 14A (accession 0001193125-26-157123) · 2026-04-15
- Filing COMPASS Pathways 8-K Item 5.02, appointment of Teri Loxam as CFO (0001816590-23-000142) · 2023-12-07
- Filing COMPASS Pathways 8-K Item 5.02(e), change-in-control vesting amendments (0001816590-25-000042) · 2025-04-16
- Filing COMPASS Pathways 8-K Item 5.07, 2026 AGM results (0001816590-26-000046) · 2026-05-28
- Filing COMPASS Pathways 8-K Item 1.01, underwriting agreement for $150m ADS offering (0001628280-26-009501) · 2026-02-19
- Filing SEC XBRL companyconcept us-gaap/NetIncomeLoss, CIK 1816590 (FY2025 10-K, 0001816590-26-000020) · 2026-03-24
- Filing SEC EDGAR ownership report listing (Forms 3/4/5) for issuer CIK 1816590; Teri Loxam reporting CIK 1829111 · 2026-09-25
- Web search result WebSearch: Teri Loxam CFO Compass Pathways biography (company leadership page) · 2026-09-25